CAS: 33342-05-1; N-(Cyclohexylcarbamoyl)-4-(2-(7-Methoxy-4,4-Dimethyl-1,3-Dioxo-3,4-Dihydroisoquinolin-2(1H)-yl)Ethyl)Benzenesulfonamide

上下游产品

benzolsulfonamid4-2-(3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-is°Chinolyl)ethylbenzolsulfonamid Cyclohexyl is°Cyanate diethyl phosphor°Chloridothioate sodium 2-isopropyl-6-methylpyrimidin-4-olatebenzolsulfonamid4-2-(3,4-Dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-is°Chinolyl)ethylbenzolsulfonamid N-cyclohexylphthalimide

异喹啉物,环己基异氰酸酯置于potassium Carbonate体系中,化学反应 5.0H,以80%的收率获得格列喹酮
参考文献:一种制备格列喹酮的方法
标题:一种制备格列喹酮的方法
摘要:本发明公开了一种制备格列喹酮的方法,以异喹啉物作为原料,异喹啉物与环己基异氰酸酯在溶剂中,在碱的作用下发生缩合反应,生成格列喹酮.本发明采用2,5‑二甲基四氢呋喃等作用作溶剂,此溶剂对异喹啉物有很好的溶解性但是对产品格列喹酮是不良溶剂,在后处理的时候只需要少量的水即可,大大减少了反应产生的废水;本发明的无水碳酸钾等常用无机碱,全无毒,利于处理.本发明的2,5二甲基四氢呋喃等溶剂沸点低,易于回收,而且体系本身不怕水,溶剂能够循环套用,降低生产成本;本发明采用回流温度,易于操作反应6小时,快速高效.

专利信息

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-8598153-B2
优先权日:2006-09-22
标题 :Method of treatment using fatty acid synthesis inhibitors
发明人：SINGH SHEO B; TOTA MICHAEL R; WANG JUN
权利人:SINGH SHEO B; TOTA MICHAEL R; WANG JUN; MERCK SHARP & DOHME
摘要:The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.

专利号:US-2022402908-A1
优先权日:2019-07-08
标题 :Cxcr6 inhibitors and methods of use
发明人：PEDDIBHOTLA SATYAMAHESHWAR; HERSHBERGER PAUL M; KIRBY RICHARD JASON; MALANY SIOBHAN; SMITH LAYTON H; MALONEY PATRICK R; SESSIONS HAMPTON; DIVLIANSKA DANIELA; PINKERTON ANTHONY B
权利人:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
摘要:Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.

专利号:US-10906888-B2
优先权日:2016-07-14
标 题:Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
发明人：CASIMIRO-GARCIA AGUSTIN; STROHBACH JOSEPH WALTER; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; CHOI CHULHO; ALLAIS CHRISTOPHE PHILIPPE; WRIGHT STEPHEN WAYNE
权利人:PFIZER
摘要:Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9018249-B2
优先权日:2011-09-13
标题 :SGLT inhibitors
发明人：JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR
权利人:JAIN RAJESH; TREHAN SANJAY; DAS JAGATTARAN; NANDA GURMEET KAUR; THUNGATHURTHI SASTRY V R S; SINGH NISHAN; SHARMA SUDHIR KUMAR; PANACEA BIOTEC LTD
摘要:The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

专利号:EP-1551403-B1
优先权日:2002-10-10
标 题 :5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
发明人：SEMPLE GRAEME; AVERBUJ CLAUDIA; SKINNER PHILIP; GHARBAOUI TAWFIK; SHIN YOUNG-JUN
权利人:ARENA PHARM INC
摘要:The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R₂ is H, halogen, C_1-12 alkyl or C_1-12 haloalkyl; and R₃ is C_3-6 cycloalkyl, C_1-12 alkyl, C_1-12 haloalkyl, C_3-6 cycloalkyl-C_1-4-alkylene, aryl-C_1-4-alkylene or heteroaryl-C_1-4-alkylene, wherein said aryl-C_1-4-alkylene and heteroaryl-C_1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.